David Schenkein is a first-generation American physician-investor who built a three-act career spanning 13 years as an academic hematologist at Tufts, 19 years leading oncology drug development including as founding CEO of Agios where he oversaw approval of the first metabolism-targeting AML drugs, and now as a GV general partner while maintaining his clinical role. He's known as a win-win or no deal partner-making specialist who pushes CEOs to be explicit about why they're partnering and warns that many non-dilutive deals are actually more dilutive than equity because of lost control and economics. David Schenkein is a first-generation American physician-investor who built a three-act career spanning 13 years as an academic hematologist at Tufts, 19 years leading oncology drug development including as founding CEO of Agios where he oversaw approval of the first metabolism-targeting AML drugs, and now as a GV general partner while maintaining his clinical role. He's known as a win-win or no deal partner-making specialist who pushes CEOs to be explicit about why they're partnering and warns that many non-dilutive deals are actually more dilutive than equity because of lost control and economics.